Concordia International Corp (CXR) Analysts See $0.71 EPS

July 24, 2017 – By Adrian Mccoy

Analysts await Concordia International Corp (TSE:CXR) to report earnings on August, 11. They expect $0.71 EPS, down 54.49 % or $0.85 from last year’s $1.56 per share. T_CXR’s profit will be $35.95M for 0.66 P/E if the $0.71 EPS becomes a reality. After $-0.49 actual EPS reported by Concordia International Corp for the previous quarter, Wall Street now forecasts -244.90 % EPS growth. The stock decreased 1.57% or $0.03 on July 24, reaching $1.88. About 165,290 shares traded. Concordia International Corp (TSE:CXR) has 0.00% since July 25, 2016 and is . It has underperformed by 16.70% the S&P500.

Concordia International Corp (TSE:CXR) Ratings Coverage

Among 4 analysts covering Concordia Healthcare Corp (TSE:CXR), 0 have Buy rating, 3 Sell and 1 Hold. Therefore 0 are positive. Concordia Healthcare Corp had 34 analyst reports since August 11, 2015 according to SRatingsIntel. RBC Capital Markets downgraded Concordia International Corp (TSE:CXR) rating on Thursday, December 8. RBC Capital Markets has “Underperform” rating and $1 target. RBC Capital Markets maintained Concordia International Corp (TSE:CXR) on Monday, October 17 with “Outperform” rating. The firm has “Sector Outperform” rating given on Wednesday, September 9 by Scotia Capital. On Monday, June 20 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of Concordia International Corp (TSE:CXR) has “Outperform” rating given on Tuesday, August 11 by RBC Capital Markets. RBC Capital Markets maintained the shares of CXR in report on Monday, November 28 with “Sector Perform” rating. The firm has “Underperform” rating by Scotia Capital given on Wednesday, January 4. Mackie downgraded Concordia International Corp (TSE:CXR) on Thursday, December 3 to “Hold” rating. The company was maintained on Tuesday, June 7 by RBC Capital Markets. RBC Capital Markets maintained Concordia International Corp (TSE:CXR) on Monday, October 24 with “Outperform” rating.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada pharmaceutical company. The company has market cap of $95.20 million. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. It currently has negative earnings.

More important recent Concordia International Corp (TSE:CXR) news were published by: which released: “Concordia International Corp. Comments on CMA Statement of Objections Related …” on March 03, 2017, also published article titled: “Concordia International Corp. Announces RedHill Biopharma Has Started …”, published: “Concordia International’s (CXRX) CEO Allan Oberman Q1 2017 Results – Earnings …” on May 10, 2017. More interesting news about Concordia International Corp (TSE:CXR) was released by: and their article: “BRIEF-Concordia International Corp reports Q1 revenue of $160.6 million” with publication date: May 10, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published.

14 + five =